相关临床试验
4
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1994
暂无试验阶段数据
已完成
3
75.0%
终止
1
25.0%
暂无批准数据
- ANGLE plc announces strategic rebrand to CelLBxHealth plc, reflecting sharpened focus on circulating tumor cell intelligence and liquid biopsy diagnostics. - Dr. Jan Groen transitions from Non-Executive Chairman to Executive Chairman, bringing 25 years of oncology diagnostics commercialization experience including successful turnaround of MDxHealth. - Company maintains cash runway through Q1 2026 while pursuing cost control measures and accelerated commercial partnerships in proteomics and genomics markets. - Strategic pivot emphasizes maximizing proprietary Parsortix platform potential by integrating existing proteomics and genomic assays with circulating tumor DNA insights.
- ANGLE's Parsortix system has enabled multiple breakthrough studies published in high-impact journals, revealing novel insights into circulating tumor cell biology and cancer metastasis mechanisms. - Research published in Nature Genetics demonstrates that CTC clusters exhibit significant genetic diversity and are up to 100 times more metastatic than individual CTCs, making them critical targets for preventing cancer spread. - Additional studies using the Parsortix platform have uncovered substantial tumor cell release during prostate and ovarian cancer surgeries, opening new avenues for understanding surgical risks and developing protective strategies. - The mechanical conditioning research in breast cancer patients revealed progressive increases in metastatic potential through the cancer cascade, potentially guiding treatment selection with anti-fibrotic drugs.
- ANGLE plc has successfully completed development of two assays for AstraZeneca: an Androgen Receptor assay for prostate cancer and a DNA damage response micronuclei assay, positioning the company for large-scale clinical trials. - Results from Eisai's Phase 2 pilot study demonstrate that ANGLE's Parsortix-based HER2 assay can effectively measure changes in breast cancer patients' HER2 status over time, offering advantages over traditional tissue biopsies. - The liquid biopsy technology shows potential to identify patients who may benefit from HER2-targeted therapies despite initially testing negative via tissue biopsy, potentially expanding treatment options and improving patient outcomes.
- A clinical trial demonstrated that digoxin, a cardiac drug, significantly reduced the size of circulating tumor cell (CTC) clusters in metastatic breast cancer patients. - The study found an average reduction of 2.2 cells per cluster after one week of low-dose digoxin treatment, decreasing the risk of metastasis. - Researchers aim to develop new molecules based on digoxin to more effectively dissolve CTC clusters and prevent cancer spread. - Angle's Parsortix system played a crucial role in identifying patients with highly metastatic CTC clusters, enabling researchers to focus treatment.
